• news

Celaid Therapeutics picked for NCC Venture Incubation Program.

Celaid Therapeutics has been adopted by the National Cancer Center Venture Incubation Program, a program that aims to support venture companies that are trying commercialize innovative medical technology, and started by the National Cancer Center Japan (President: Hitoshi Nakagama, Chuo-ku, Tokyo) and Tokyo Edge Capital Partners Co., Ltd. (Bunkyo-ku, Tokyo, President and Managing Partner, Tomotaka Goji).

NCC Venture Incubation Program support team for 2021 decided.

Through this program, we plan to make significant progress in realizing new regenerative medicine.

Copyright© セレイドセラピューティクス - 細胞治療(造血幹細胞) , 2024 All Rights Reserved Powered by STINGER.